ProMetic Life Sciences (PLI) Sets New 1-Year Low at $0.40

Shares of ProMetic Life Sciences Inc. (TSE:PLI) hit a new 52-week low during trading on Monday . The stock traded as low as C$0.40 and last traded at C$0.40, with a volume of 797331 shares. The stock had previously closed at C$0.43.

Separately, TD Securities lowered shares of ProMetic Life Sciences from a “speculative buy” rating to a “hold” rating and lowered their price objective for the stock from C$2.00 to C$1.00 in a report on Friday, August 17th.

ProMetic Life Sciences (TSE:PLI) last released its earnings results on Tuesday, August 14th. The company reported C($0.05) earnings per share (EPS) for the quarter. The firm had revenue of C$20.16 million for the quarter, compared to analysts’ expectations of C$5.50 million.

ILLEGAL ACTIVITY NOTICE: “ProMetic Life Sciences (PLI) Sets New 1-Year Low at $0.40” was originally reported by WKRB News and is the property of of WKRB News. If you are viewing this article on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.wkrb13.com/2018/11/07/prometic-life-sciences-pli-sets-new-1-year-low-at-0-40.html.

About ProMetic Life Sciences (TSE:PLI)

ProMetic Life Sciences Inc, a biopharmaceutical company, develops bioseparations, plasma-derived therapeutics, and small-molecule therapeutic products. It operates through three segments: Small-Molecule Therapeutics, Plasma-Derived Therapeutics, and Bioseparation Technologies. The company offers its technology platform for purification of biologics, drug development, proteomics, and elimination of pathogens; and develops small molecule therapeutic products targeting unmet medical needs in the fields of fibrosis, inflammation, autoimmune diseases, oncology, and nephropathies.

Further Reading: What does cost of debt say about a company’s financial health?

Receive News & Ratings for ProMetic Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply